Stakeholder Insight: Parkinson's Disease - Evidence of Neuroprotection Essential to Progress Treatment Dynamics
Posted on: Tuesday, 5 February 2008, 15:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c81848) has announced the addition of Stakeholder Insight: Parkinson's Disease - Evidence of neuroprotection essential to progress treatment dynamics to their offering.
Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); with patients typically being diagnosed in their early sixties and living for over 18 years after the onset of first symptoms.
Scope
- Overview of epidemiology, presentation, and diagnostic assessment in PD
- Breakdown of first-line treatment regimens for early-, mid-, and advanced-stage disease, with analysis of second-line add-on and switching dynamics
- Influences on neurologists treatment decisions and their perception of current brands
- Evaluation of treatment outcomes and surgical procedures for PD
Highlights of this title
Neurologists indicated that the DAs Mirapex (pramipexole) and Requip (ropinirole) are generally the initial treatment of choice for younger presenting patients. While levodopa is reserved for patients over 65 years of age, neurologists may prescribe the MAOIs selegiline and rasagiline (Azilect) in young patients with only mild symptoms at onset.
Neurologists indicated that only 36% of advanced-stage PD patients are adequately controlled by pharmacological therapy. Considering the even distribution of patient severities (30% early-stage, 39% mid-stage and 31% advanced-stage), the advanced-stage patient group is particularly poorly served by current therapies.
Neurologists estimated that approximately 9% of all PD patients will eventually require surgery. Deep Brain Stimulation is by far the most common surgical procedure used in the 7MM and neurologists indicated that over 70% of patients receiving it experience both a reduction in PD symptoms and a reduction in the dose of pharmacological medication.
Key reasons to purchase this title
- Target prescribers more effectively, through an understanding of prescribing behavior and its influences
- Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Content Outline:
About Us Healthcare
Chapter 1 Executive Summary
Chapter 2 Introduction And Scope
Chapter 3 Country Treatment Trees
Chapter 4 Epidemiology And Patient Segmentation
Chapter 5 Presentation, Diagnosis And Comorbidities
Chapter 6 Treatment Options And Guidelines
Chapter 7 Prescribing Trends In Parkinsons Disease
Chapter 8 Prescribing Influences And Brand Assessment
Chapter 9 Treatments Outcomes And Surgery
Bibliography
Appendix A
Appendix B
List of Tables
List of Figures
Companies Mentioned:
- AM nv
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Britannia Building Society
- Cytokine PharmaSciences, Inc
- Danka Business Systems PLC
- Electronic Data Systems Corporation
- Eli Lilly and Company
- GlaxoSmithKline Plc
- Gottschalks Inc
- H.J. Heinz Company
- Hughes Communications Inc
- IMS Health
- Insight Communications Company, Inc.
- Medtronic, Inc.
- Merck & Co., Inc.
- NICE Systems Ltd
- Novartis AG
- Pepper Construction Group, LLC
- Pfizer Inc
- Safety Insurance Group, Inc.
- Schwarz Pharma AG
- Solvay Group
- Taylor Corporation
- Vernalis Group PLC
For more information visit http://www.researchandmarkets.com/reports/c81848
Source: Datamonitor
Source: Business Wire
Related Articles
- The Lancet Neurology Publishes Clinical Results of PBT2 in Alzheimer's Disease Patients
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Washington Redskins Players, Kidney Disease Patients, Advocates Unveil National Petition Calling on Congress for Additional Kidney Care Support
- Groundbreaking Clinical Trial at Mary Crowley Significantly Increases Survival in End-Stage Head and Neck Cancer Patients
- Osiris Therapeutics Reports Positive Results for Prochymal(TM) As a Rescue Agent in Pediatric Patients With End-Stage Graft Vs. Host Disease
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Genzyme Begins Trial of Myozyme(R) for Patients With Late-Onset Pompe Disease
- New Study Shows Significant Improvements in Health-Related Quality-of-Life Measures in Chronic Obstructive Pulmonary Disease Patients Using SPIRIVA(R) HandiHaler(R)
- AmpliMed Initiates Multi-Center, Phase I/II Study of Amplimexon Plus Gemcitabine in Patients With Previously Untreated, Advanced Pancreatic Adenocarcinoma
- Pretransplant Psychiatric and Medical Comorbidity of Alcoholic Liver Disease Patients Who Received Liver Transplant
 |
 |
User Comments (0)
RSS Feeds